STATCenter·
STAT+: Ultragenyx cuts staff after another study fails
Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.
Read at STAT →
Health · 1 sources covering this
STAT+: Ultragenyx cuts staff after another study fails
Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/7bb8855a3618fd5a900c1019bfdc70b82ca45173" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Ultragenyx cuts staff after another study fails"></iframe>
